HK1038308A1 - Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix - Google Patents

Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix

Info

Publication number
HK1038308A1
HK1038308A1 HK01108540A HK01108540A HK1038308A1 HK 1038308 A1 HK1038308 A1 HK 1038308A1 HK 01108540 A HK01108540 A HK 01108540A HK 01108540 A HK01108540 A HK 01108540A HK 1038308 A1 HK1038308 A1 HK 1038308A1
Authority
HK
Hong Kong
Prior art keywords
overproduction
accumulation
pharmaceutical composition
extracellular matrix
inhibitory effect
Prior art date
Application number
HK01108540A
Other languages
English (en)
Inventor
Satoshi Sasaki
Yoshihiko Sumi
Reginald Colin Hughes
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Publication of HK1038308A1 publication Critical patent/HK1038308A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01108540A 1998-08-06 2001-12-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix HK1038308A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23349998 1998-08-06
PCT/JP1999/004238 WO2000007624A2 (en) 1998-08-06 1999-08-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix

Publications (1)

Publication Number Publication Date
HK1038308A1 true HK1038308A1 (en) 2002-03-15

Family

ID=16955990

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01108540A HK1038308A1 (en) 1998-08-06 2001-12-05 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix

Country Status (6)

Country Link
EP (1) EP1104307B1 (de)
JP (1) JP2002522398A (de)
AU (1) AU5065399A (de)
DE (1) DE69931791T2 (de)
HK (1) HK1038308A1 (de)
WO (1) WO2000007624A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100172D0 (sv) 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
JP2002322082A (ja) * 2001-04-26 2002-11-08 Purotejiin:Kk 腎炎の予防・治療剤
AU2004229399B2 (en) * 2003-04-07 2010-08-05 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
US20050053664A1 (en) 2003-09-08 2005-03-10 Eliezer Zomer Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
EP2926818A1 (de) 2004-03-26 2015-10-07 La Jolla Pharmaceutical Company Modifizierte pektine, zusammensetzungen und zugehörige verfahren
JP2005314252A (ja) * 2004-04-27 2005-11-10 Okayama Univ 糖尿病性腎症の予防・治療剤
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
CA2942320A1 (en) * 2014-03-10 2015-09-17 La Jolla Pharmaceutical Company Compositions and methods for treating kidney disorders
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
EP4125937A4 (de) * 2020-03-23 2024-05-22 G3P, Inc. Verfahren und zusammensetzungen zur prävention und behandlung von fibrose infolge einer coronavirusinfektion

Also Published As

Publication number Publication date
EP1104307B1 (de) 2006-06-07
AU5065399A (en) 2000-02-28
DE69931791D1 (de) 2006-07-20
EP1104307A2 (de) 2001-06-06
WO2000007624A3 (en) 2000-06-22
DE69931791T2 (de) 2007-05-24
JP2002522398A (ja) 2002-07-23
WO2000007624A2 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
HUP0103575A3 (en) Inhibitors of caspases, pharmaceutical compositions comprising thereof and their use
HUP0101130A3 (en) Aminoindan derivatives and pharmaceutical compositions comprising them
HUP0103406A3 (en) 1h-imidazopyridine derivatives and pharmaceutical compositions thereof
HUP0102990A3 (en) Tetrahydroimidazo-naphtyridine derivatives and pharmaceutical compositions thereof
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
HUP0000965A3 (en) Pyrrolidine derivatives having phospolipase a2 inhibitory activity and pharmaceutical compositions containing the same
HUP0103874A3 (en) Use of antibiotics and pharmaceutical compositions comprising thereof
HUP0002942A3 (en) Peptides having serine protease inhibiting effect pharmaceutical compositions comprising thereof and their use
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
HUP0100149A3 (en) Antipicornaviral peptide derivatives pharmaceutical compositions comprising thereof and their use
HUP9902655A3 (en) Pharmaceutical composition of hedgehog proteins and use thereof
HUP9801227A3 (en) Pharmaceutical compositions comprising monoamine oxidase b inhibitors and their use
HUP0103203A3 (en) Azaadamantane derivatives and pharmaceutical compositions thereof
HK1038308A1 (en) Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
IL138247A (en) Substituted bisindolymaleimides for the inhibition of cell proliferation and pharmaceutical compositions comprising them
HUP0100082A3 (en) Thrombin inhibitor, peptide derivatives, pharmaceutical compositions comprising thereof and their use
IL117247A (en) Pharmaceutical compositions comprising protease inhibitors and quinoxalines
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
HUP0002331A3 (en) 20-aralkyl-5alpha-pregnane derivatives and pharmaceutical compositions thereof
GB9929302D0 (en) Benzyl tetralins compositions and uses thereof
HUP0102109A3 (en) Sweetener composition and uses thereof
HUP0101733A3 (en) Pharmaceutical compositions containing sulfonyl-dipeptides and their use
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
IL125908A0 (en) Peptides and pharmaceutical compositions comprising same
GB9803521D0 (en) New compounds and pharmaceutical compositions thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100805